(Information sent by the signatory company)
- MitoSense Inc. and Uppsala University, in collaboration with the Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation, announce a breakthrough in mitochondrial preservation
PLYMOUTH, Mass., Jan. 25, 2024 /PRNewswire/ -- MitoSense Inc, a leading innovative biotechnology company focused on neurodegenerative diseases, in collaboration with Uppsala University, the Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation in Baton Rouge, Louisiana, USA, proudly announces a historic scientific breakthrough in the field of mitochondrial preservation, a key element in mitochondrial transplant therapies.
The study "Extracellular Vesicles from Mesenchymal Stromal Cells (imEVs) Enhance Cold Preservation of Isolated Mitochondria" reveals an innovative technique to maintain the viability of isolated mitochondria during cold storage. This method, which uses extracellular vesicles from mesenchymal stromal cells (imEVs), represents a significant advance in mitochondrial medicine. Mitochondrial organelle transplantation (MOT™) is an innovative strategy for the treatment of mitochondrial dysfunctions such as neurodegenerative disease lesions, Parkinson's, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease. However, one of the challenges for its widespread use is a methodology for the preservation of isolated mitochondria.
Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, key collaborators on this research, described the study as a "milestone in mitochondrial science." They noted the important implications of this discovery in opening new therapeutic avenues for conditions related to mitochondrial dysfunction.
Van Hipp, President of MitoSense, highlighted the importance of collaboration to achieve this breakthrough. "The partnership with the Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he said.
MitoSense Inc. has been a pioneer in the development of advanced therapies for neurodegenerative diseases. Its patented MOT™ technology has shown promising results in the treatment of mitochondrial dysfunction. This technology is now being explored in a project sponsored by CAMP/Vinnova ( https://atmpsweden.se/), targeting ischemia-reperfusion injury following myocardial infarction.
This collaborative effort represents an important addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and improving patient care.
About MitoSense Inc.: MitoSense Inc. is at the forefront of biotechnology, dedicated to the development of innovative therapies for neurodegenerative diseases. The company's commitment to advancing mitochondrial health is evident in its ongoing research and exploration of novel treatments.
Logo - https://mma.prnewswire.com/media/1735129...
View original content: https://www.prnewswire.com/news-releases/mitosense-inc-y-la-universidad-de-uppsala-anuncian-un-avance-en-la-preservacion-mitocondrial-302044502.html